News

Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...
Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...
Hims & Hers (NYSE: HIMS) and UnitedHealth (NYSE: UNH) suffered huge stock price decreases that attracted investors looking to ...
Novo Nordisk just killed its deal with Hims & Hers. But Hims might come out stronger after this development. Read why the ...
Should you invest $1,000 in Hims & Hers Health right now? Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t ...
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN HIMS & HERS HEALTH, INC. (HIMS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 25, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING ...
Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.
Discover how Uber and Hims & Hers Health are positioned for growth in FY26, offering unique opportunities in the mobility and ...
New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...
Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...